Amoy Diagnostics Co Ltd (300685) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amoy Diagnostics Co Ltd (300685) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥110.87 Million ≈ $16.22 Million USD) by net assets (CN¥1.97 Billion ≈ $288.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Amoy Diagnostics Co Ltd for the company's overall valuation and market capitalisation.
Amoy Diagnostics Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Amoy Diagnostics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amoy Diagnostics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amoy Diagnostics Co Ltd ranked by their cash flow conversion efficiency. Explore Amoy Diagnostics Co Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mcmillan Shakespeare Ltd
AU:MMS
|
-0.294x |
|
Burford Capital Ltd
NYSE:BUR
|
-0.058x |
|
SANDUR MANGANESE AND IRON ORES LTD
NSE:SANDUMA
|
0.104x |
|
Shanghai Action Education Technology CO.LTD.
SHG:605098
|
N/A |
|
Foxsemicon Integrated Technology Inc
TW:3413
|
-0.012x |
|
Shantou Wanshun Package Material
SHE:300057
|
-0.017x |
|
Black Peony Group Co Ltd
SHG:600510
|
0.000x |
|
Astra Agro Lestari Tbk
JK:AALI
|
0.063x |
Annual Cash Flow Conversion Efficiency for Amoy Diagnostics Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Amoy Diagnostics Co Ltd from 2012 to 2025. View Amoy Diagnostics Co Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.06 Billion ≈ $300.85 Million |
CN¥364.82 Million ≈ $53.39 Million |
0.177x | -4.32% |
| 2024-12-31 | CN¥1.84 Billion ≈ $269.73 Million |
CN¥341.85 Million ≈ $50.02 Million |
0.185x | +5.75% |
| 2023-12-31 | CN¥1.70 Billion ≈ $249.25 Million |
CN¥298.72 Million ≈ $43.71 Million |
0.175x | +76.47% |
| 2022-12-31 | CN¥1.50 Billion ≈ $219.46 Million |
CN¥149.04 Million ≈ $21.81 Million |
0.099x | -19.06% |
| 2021-12-31 | CN¥1.37 Billion ≈ $200.42 Million |
CN¥168.16 Million ≈ $24.61 Million |
0.123x | -37.22% |
| 2020-12-31 | CN¥1.13 Billion ≈ $165.13 Million |
CN¥220.69 Million ≈ $32.29 Million |
0.196x | +16.43% |
| 2019-12-31 | CN¥902.11 Million ≈ $132.01 Million |
CN¥151.52 Million ≈ $22.17 Million |
0.168x | +36.02% |
| 2018-12-31 | CN¥756.74 Million ≈ $110.73 Million |
CN¥93.45 Million ≈ $13.67 Million |
0.123x | -12.76% |
| 2017-12-31 | CN¥649.20 Million ≈ $95.00 Million |
CN¥91.89 Million ≈ $13.45 Million |
0.142x | +35.41% |
| 2016-12-31 | CN¥307.91 Million ≈ $45.06 Million |
CN¥32.18 Million ≈ $4.71 Million |
0.105x | +35.70% |
| 2015-12-31 | CN¥247.90 Million ≈ $36.28 Million |
CN¥19.10 Million ≈ $2.79 Million |
0.077x | -57.03% |
| 2014-12-31 | CN¥87.54 Million ≈ $12.81 Million |
CN¥15.69 Million ≈ $2.30 Million |
0.179x | -17.67% |
| 2013-12-31 | CN¥39.30 Million ≈ $5.75 Million |
CN¥8.56 Million ≈ $1.25 Million |
0.218x | +1888.50% |
| 2012-12-31 | CN¥17.25 Million ≈ $2.52 Million |
CN¥-210.00K ≈ $-30.73K |
-0.012x | -- |
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more